澳门威尼斯人娱乐

MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 AUGUST 2024

VOLUNTARY ANNOUNCEMENT - PHASE III STUDY RESULTS OF CULMERCICLIB IN COMBINATION WITH FULVESTRANT FOR TREATMENT OF HR+/HER2- ADVANCED BREAST CANCER FOLLOWING ENDOCRINE TREATMENT TO BE PRESENTED AT 2024 CSCO

VOLUNTARY ANNOUNCEMENT - POSITIVE RESULTS ON PHASE III STUDY OF ANLOTINIB HYDROCHLORIDE CAPSULE IN COMBINATION WITH PENPULIMAB FOR FIRST-LINE TREATMENT OF ADVANCED HEPATOCELLULAR CARCINOMA

VOLUNTARY ANNOUNCEMENT - THREE RESEARCH RESULTS OF "TQC3721 (PDE3/4 INHIBITOR)" AND "TQC2731 (TSLP MONOCLONAL ANTIBODY)" WILL BE PRESENTED AT ERS 2024

INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 JUNE 2024

INTERIM DIVIDEND FOR 2024

VOLUNTARY ANNOUNCEMENT - ACCEPTANCE OF NEW INDICATION APPLICATION FOR MARKETING OF BENMELSTOBART INJECTION IN COMBINATION WITH ANLOTINIB HYDROCHLORIDE CAPSULE FOR FIRST-LINE TREATMENT OF ADVANCED RENAL CELL CARINOMA

NOTIFICATION OF BOARD MEETING